(1S-endo)-(3-Bromo-7,7-dimethyl-2-oxobicyclo(2.2.1)hept-1-yl)methanesulphonic acid | 67999-30-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1S-endo)-(3-Bromo-7,7-dimethyl-2-oxobicyclo(2.2.1)hept-1-yl)methanesulphonic acid
• 英文别名: [(1S)-3-bromo-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
• CAS: 67999-30-8
• 化学式: C₁₀H₁₅BrO₄S
• 分子量: 311.19
• InChiKey: XUJHKPSBHDQIOD-HNQUHTCLSA-N

物化性质

• 熔点：
  118-120 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 包装等级：
  III
• 危险品运输编号：
  UN 3261 8/PG 2

文献信息

• Process for production of delta-9- tetrahydrocannabinol
  申请人：Burdick C. David

  公开号：US20070093665A1

  公开（公告）日：2007-04-26

  The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R 8 , R 9 , and R 10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R 1 , R 2 , and R 3 defined herein.

  本发明涉及一种制备Δ-9-四氢大麻酚化合物或其衍生物的方法，涉及将第一中间化合物与基于有机铝的Lewis酸催化剂处理，在有效条件下产生Δ-9-四氢大麻酚化合物或其衍生物。本发明的另一个方面涉及一种制备大麻二酚或大麻二酚盐化合物的方法，涉及在金属三氟甲磺酸盐催化剂存在下，将第一起始化合物与第二起始化合物反应，在有效条件下形成大麻二酚或大麻二酚盐化合物。本发明还涉及一个化合物，其化学式为：其中R8、R9和R10相同或不同，并且独立地选自H、取代或未取代的烷基、取代或未取代的芳基、取代或未取代的杂环芳基或卤素，其中R1、R2和R3在此定义。
• Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP2599781A1

  公开（公告）日：2013-06-05

  There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

  提供了西格列汀的盐和多晶形式，其制备方法以及包含它们的制药组合物。
• PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF
  申请人：Padi Pratap Reddy

  公开号：US20100274017A1

  公开（公告）日：2010-10-28

  There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

  提供了西格列汀的盐和多晶形态，以及其制备方法和包含其的药物组合物。
• PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
  申请人：Dr. Reddy's Laboratories, Inc.

  公开号：US20140128607A1

  公开（公告）日：2014-05-08

  There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

  提供了西格列汀的盐和多型体，其制备过程以及包含它们的药物组合物。
• Processes for the production of cannabidiol derivatives and intermediates thereof
  申请人：Albany Molecular Research, Inc.

  公开号：EP2578561A1

  公开（公告）日：2013-04-10

  This invention relates to a process for the preparation of a product compound of the formula: wherein: R1 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R2 is H, OH, protected hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, acyl, aryl, or heteroaryl; R3 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R4 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl; and R6 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl.

  本发明涉及一种制备公式化合物的过程：其中：R1为氢，取代或未取代烷基，羧酸酯或酰基；R2为氢，羟基，保护羟基，取代或未取代烷基，烯基，炔基，酰基，芳基或杂环芳基；R3为氢，取代或未取代烷基，羧酸酯或酰基；R4为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基；R6为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基。